Viking Therapeutics, Inc. (VKTX) Stock Score, Valuation & Financial Research

Viking Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for VKTX

Viking Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 28.38. These figures are a research snapshot, not a buy or sell recommendation.

What Viking Therapeutics, Inc. does

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Viking Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and potential future licensing or collaboration agreements to fund the research and development of novel therapies for metabolic and endocrine disorders.

Products and services

  • The company is developing a pipeline of drug candidates, including VK2735 for obesity and metabolic disorders, and VK2809 for non-alcoholic steatohepatitis (NASH) and lipid disorders.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its drug candidates; specific suppliers are generally unnamed. Source

Business relationships and partnerships

  • Corden Pharma Colorado, Inc. — A multi-year manufacturing agreement for API and final finished product capacity to support clinical and potential commercial supply. Source

Business strengths to evaluate

  • Clinical-stage pipeline targeting large metabolic and endocrine market opportunities Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers and clinical trial sites Source
  • Need for additional capital to fund research and development Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

VKTX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 28.38
Market capitalization:
3.31B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -534.8M
Free cash flow:
USD -278.69M
Cash:
USD 125.75M
Total debt:
USD 4.09M
EPS:
USD -4.66

What stands out

  • Free cash flow is USD -278.69M, negative for the stored period.
  • The balance sheet shows USD 125.75M of cash versus USD 4.09M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 121.66M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for VKTX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can VKTX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is VKTX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for VKTX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of VKTX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research VKTX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.